Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia

Pharmaceutical Research

Volumn 26, Issue 4, 2009, Pages 958-964

  Qu, Hai Yan ^a,b   Xiao, Ya Wei ^a   Jiang, Gui Hua ^a   Wang, Zhi Yun ^a   Zhang, Yun ^a   Zhang, Mei ^a  

^a Qilu Hospital of Shandong University   (China)

^b SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

Author keywords

Atorvastatin; Endothelium; Hypercholesterolemia; Rosuvastatin; Serum adiponectin

Indexed keywords

ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; ENDOTHELIN 1; GELATINASE B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSUVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADIPONECTIN; ADULT; AGED; BIOLOGICAL MARKERS; BRACHIAL ARTERY; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 61449170959     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9798-6     Document Type: Article

References (46)

1. M. Matsubara S. Maruoka S. Katayose 2002 Decreased plasma adiponectin concentrations in women with dyslipidemia J. Clin. Endocrinol. Metab. 87 2764 2769
2. P.J. Havel 2004 Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism Diabetes 53 suppl 1 S143 151
3. M. Chandran S. A. Phillips T. Ciaraldi R. R. Henry 2003 Adiponectin: more than just another fat cell hormone? Diabetes Care 26 2442 2450
4. T. Kadowaki T. Yamauchi 2005 Adiponectin and adiponectin receptors Endocr. Rev. 26 439 451
5. K. Miyagishima S. Hiramitsu S. Kato 2007 Efficacy of atorvastatin therapy in ischaemic heart disease-effects on oxidized low-density lipoprotein and adiponectin J. Int. Med. Res. 35 534 539
6. K. K. Koh M. J. Quon S. H. Han W. J. Chung J. Y. Ahn Y. H. Seo I. S. Choi E. K. Shin 2005 Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia J. Am. Coll. Cardiol. 45 1649 1653
7. S. Wissen T. J. Smilde E. Groot BA. Hutten J. J. Kastelein A. F. Stalenhoef 2003 The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study Eur. J. Cardiovasc. Prev. Rehabil. 10 451 455
8. K. K. Koh C. Cardillo M. N. Bui L. Hathaway G. Csako M. A. Waclawiw J. A. Panza R. O. III Cannon 1999 Vascular Effects of estrogen and cholesterol-lowering therapies on vascular function in hypercholesterolemic postmenopausal women Circulation 99 354 360
9. R. C. Schlant, and R. W. Alexander. Hurst's the heart: Arteries and veins. 8McGraw-Hill, New York, 1995.
10. A. Niemann-Jönsson P. Dimayuga S. Jovinge F. Calara M. P. S. Ares G. N. Fredrikson J. Nilsson 2000 Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor- expression Arterioscler. Thromb. Vasc. Biol. 20 2205 2211
11. K. K. Ray C. P. Cannon P. Ganz 2006 Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am. J. Cardiol. 98 18P 25P
12. G. G. Schwartz A. G. Olsson M. D. Ezekowitz P. Ganz M. F. Oliver D. Waters A. Zeiher B. R. Chaitman S. Leslie T. Stern 2001 Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 1711 1718
13. T. C. Andrews C. M. Ballantgne J. A. Hsia J. H. Kramer 2001 Achieving and maintaining National Cholesterol Education Program Low-density lipoprotein cholesterol goals with five statins Am. J. Med. 111 185 191
14. A. Cheng-Lai 2003 Rosuvastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia Heart Disease 5 72 78
15. P. H. Jones M. H. Davidson E. A. Stein H. E. Bays J. M. McKenney E. Miller V. A. Cain J. W. Blasetto STELLAR Study Group 2003 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR*Trial). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults Am. J. Cardiol. 92 152 160
16. P. Libby, R. O. Bonow, D. L. Mann, D. P. Zipes, and E. Braunwald. Braunwald's heart disease: A textbook of cardiovascular medicine. 8Saunders, USA, 2007.
17. S. H. Johnsen E. B. Mathiesen E. Fosse O. Joakimsen E. Stensland-Bugge I. Njølstad E. Arnesen 2005 Elevated high-density lipoprotein cholesterol levels are protective against plaque progression Circulation 112 498 504
18. S. E. Nissen E. M Tuzcu P. Schoenhagen T. Crowe W. J. Sasiela J. Tsai J. Orazem R. D. Magorien C. O. 'Shaughnessy P. Ganz the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators 2005 Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N. Engl. J. Med. 352 29 38
19. G. Weitz-Schmidt K. Welzenbach V. Brinkmann T. Kamata J. Kallen C. Bruns S. Cottens Y. Takada U. Hommel 2001 Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site Nat. Med. 7 687 692
20. T. Bourcier P. Libby 2000 HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells Arterioscler. Thromb. Vasc. Biol. 20 556 562
21. A. Undas K. E. Brummel-Ziedins K. G. Mann 2005 Statins and blood coagulation Arterioscler. Thromb. Vasc. Biol. 25 287 294
22. L. O. Jensen P. Thayssen K. E. Pedersen S. Stender T. Haghfelt 2004 Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study Circulation 110 265 270
23. K. J. Molloy M. M. Thompson E. C. Schwalbe P. R. Bell A. R. Naylor I. M. Loftus 2004 Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively Am. J. Cardiol. 94 144 146
24. J. Calles-Escandon M. Cipolla 2001 Diabetes and endothelial dysfunction: A clinical perspective Endocr. Rev. 22 36
25. M. Crisby G. Nordin-Fredriksson P. K. Shah J. Yano J. Zhu J. Nilsson 2001 Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 926 933
26. M. Juonala J. S. Viikari T. Laitinen J. Marniemi H. Helenius T. Ronnemaa O. T. Raitakari 2004 Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns study Circulation 110 2918 2923
27. S. H. Wilson R. D. Simari P. J. Best T. E. Peterson L. O. Lerman M. Aviram K. A. Nath D. R. Jr Holmes A. Lerman 2001 Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering Arterioscler Thromb Vasc Biol 21 546 554
28. J. K. Williams G. K. Sukhova D. M. Herrington P. Libby 1998 Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys J. Am. Coll. Cardiol. 31 684 691
29. I. V. Sergienko E. I. U. Samoǐlenko V. P. Masenko M. V. Ezhov A. B. Sumarokov G. A. Tkachev O. A. Pogorelova T. V. Balakhonova V. G. Naumov 2006 Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease Kardiologiia 46 4 8
30. E. Ter Avest E. J. Abbink S. Holewijn J. de Graaf C. J. Tack A. F. Stalenhoef 2005 Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH) Curr. Med. Res. Opin. 21 1469 1476
31. R. Ross 1993 The pathogenesis of atherosclerosis: a perspective for the 1990s Nature 362 801 809
32. D. M. Maahs L. G. Ogden G. L. Kinney P. Wadwa J. K. Snell-Bergeon D. Dabelea J. E. Hokanson J. Ehrlich R. H. Eckel M. Rewers 2005 Low plasma adiponectin levels predict progression of coronary artery calcification Circulation 111 747 753
33. M. B. Schulze E. B. Rimm I. Shai N. Rifai F. B. Hu 2004 Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes Diabetes Care 27 1680 1687
34. M. Cnop P. J. Havel K. M. Utzschneider D. B. Carr M. K. Sinha E. J. Boyko B. M. Retzlaff R. H. Knopp J. D. Brunzell S. E. Kahn 2003 Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex Diabetologia 46 459 469
35. T. Yamauchi K. Hara N. Kubota Y. Terauchi K. Tobe P. Froguel R. Nagai T. Kadowaki 2003 Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine Curr. Drug Targets Immune. Endocr. Metabol. Disord. 3 243 254
36. C. -J. Li H. -W. Sun F. -L. Zhu L. Chen Y. -Y. Rong Y. Zhang M. Zhang 2007 Local Adiponectin treatment reduces atherosclerotic plaque size in rabbits J. Endocrinol. 193 137 145
37. T. Pischon C. J. Girman G. S. Hotamisligil N. Rifai F. B. Hu E. B. Rimm 2004 Plasma adiponectin levels and risk of myocardial infarction in men J. Am. Med. Assoc. 291 1730 1737
38. H. Chen M. Montagnani T. Funahashi I. Shimomura M. J. Quon 2003 Adiponectin stimulates production of nitric oxide in vascular endothelial cells J. Biol. Chem. 278 45021 45026
39. H. Kato H. Kashiwagi M. Shiraga S. Tadokoro T. Kamae H. Ujiie S. Honda S. Miyata Y. Ijiri J. Yamamoto N. Maeda T. Funahashi Y. Kurata I. Shimomura Y. Tomiyama Y. Kanakura 2006 Adiponectin acts as an endogenous antithrombotic factor Arterioscler. Thromb. Vasc. Biol. 26 224 230
40. G. A. Laughlin E. Barrett-Connor S. May C. Langenberg 2007 Association of Adiponectin with coronary heart disease and mortality: The Rancho Bernardo study Am. J. Epidemiol. 165 164 174
41. S. Devaraj D. Siegel I. Jialal 2007 Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome Am. J. Cardiol. 100 1397 1399
42. I. Gouni-Berthold H. K. Berthold J. P. Chamberland W. Krone C. S. Mantzoros 2008 Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men Clin. Endocrinol. (Oxf). 68 536 541
43. S. Sugiyama H. Fukushima K. Kugiyama H. Maruyoshi S. Kojima T. Funahashi T. Sakamoto Y. Horibata K. Watanabe H. Koga K. Sugamura F. Otsuka I. Shimomura H. Ogawa 2007 Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease Atherosclerosis 194 e43 51
44. W. Mauser N. Perwitz B. Meier M. Fasshauer J. Klein 2007 Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake Eur. J. Pharmacol. 564 37 46
45. J. Q. Li S. P. Zhao Q. Z. Li Y. C. Cai L. R. Wu Y. Fang P. Li 2006 Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits Clin. Chim. Acta. 370 57 62
46. C. S. Chu K. T. Lee M. Y. Lee H. M. Su W. C. Voon S. H. Sheu W. T. Lai 2006 Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Am. J. Cardiol. 97 646 650